معرفی
Ryoki Arimoto is a Clinical Research Fellow at the Heart and Renal Studies Group within the Clinical Trial Service Unit (CTSU) of the Nuffield Department of Population Health, University of Oxford, joining in February 2024 to work on EMPA-KIDNEY and emerging renal trials like EASi-KIDNEY on an out-of-programme research basis while pursuing a higher degree.
His educational background includes:
- Medical degree from King’s College London (2014)
- Foundation training and intensive care experience at University Hospitals Plymouth NHS Trust
- Core medical training in Oxford Deanery (2017)
- Higher specialty training in nephrology and intensive care medicine (2019)
His research centers on nephrology and renal clinical trials, specifically evaluating empagliflozin for chronic kidney disease in the EMPA-KIDNEY trial, with synergistic focus on cardiovascular outcomes and critical care intersections due to his intensive care background. Current work emphasizes large-scale therapeutic interventions for renal pathologies.
As part of CTSU’s Heart and Renal Studies Group, he contributes to globally significant trials improving cardiovascular and renal disease treatment. His fellowship integrates clinical training with research toward an advanced academic degree.